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frequency of neonatal complications in babies with higher CSBC. Most noteworthy was that the highest CSBC (17.0 mgll) was in a baby whose mother was a professional photographer. This study suggests that there is variation in CSBC and that occupational exposure to bromides from use or processing of photographic film may cause increased CSBC. 
It i s d i f f i c u l t t o achieve a t h e r a p e u t i c range r a p i d l y because of individual v a r i a t i o n s i n clearance (C1) and d i s t r i b ut i o n volume (Vd). Sheiner e t a 1 prospectively v a l i d a t e d a Baye s i a n approach t o i n d i v i d u a l i z i n g C1 and Vd i n a d u l t s .
We have studied t h e u s e f u l n e s s of t h i s microcomputer approach i n t h e neonate. The c h a r t s of 11 newborns t r e a t e d with theophylline were r e t r o s p e c t i v e l y reviewed. Average v a l u e s f o r C1 and Vd taken from t h e l i t e r a t u r e were assumed f o r each i n f a n t . I n i t i a l estimates wene revised with t h e f i r s t serum l e v e l . Individualized C1 and Vd were used t o p r e d i c t t h e second theophylline l e v e l . P r e d i c t i o n s were not s i g n i f i c a n t l y d i f f e r e n t from measured l e v e l s . We found t h a t Bayesian theophylline dosing program could e s t i m a t e an i n d i v i d u a l neonate's theophylline C1 and Vd with a s few a s one serum l e v e l with acceptable accuracy.
Gentamicin dosing d e c i s i o n s were then studied p r o s p e c t i v e l y . Serum l e v e l s were obtained immediately before t h e second dose. Published v a l u e s f o r C1 and Vd were individualized using t h e trough l e v e l and t h e Bayesian program. Dose r e v i s i o n s were made using i n d i v i d u a l C1 and Vd. Followup l e v e l s were obtained i n 72-96 hours. I n 19 of 20 i n f a n t s , followup l e v e l s were i n t h e t h e r a p e u t i c range. P r e d i c t i o n s were n o t s i g n i f i c a n t l y d i f f e r e n t from measured l e v e l s . We conclude t h a t dosing schedules which a r e individualized based on 1 serum l e v e l and t h e Bayesian microcomputer program make achieving t h e r a p e u t i c l e v e l s quick and accurate.
FETAL RITODRINE EXPOSURE AND NEONATAL OUTCOME. M.N. R i t o d r i n e Hydrochloride (R) experience was reviewed a f t e r t h e f i r s t two y e a r s of r e g u l a r use (7181-6183).
Of t h e 202 women t r e a t e d , 159 (78%) c a r r i e d t h e pregnancy t o 35 weeks o r g r e a t e r . Neonatal outcomes including birthweight (BW), g e s t a t i o n a l age (GA), Apgar scores, hypoglycemia, hyperbilirubinemia, RDS, IUGR and m o r t a l i t y were c o r r e l a t e d with (1) duration of exposure, (2) o n s e t of exposure and (3) i n t e r v a l from c e s s a t i o n of exposure t o d e l i v e r y . I n f a n t s exposed t o R f o r 6 wks (X=11.4) were signif i c a n t l y heavier (3109g v s 2884g, pC.01) than i n f a n t s exposed f o r (6' wks (X=3.6). This could be accounted f o r by a s i g n i f i c a n t d i f f e r e n c e i n the corresponding G A a t b i r t h (38.9 v s 37.4 wks, ~< . 0 0 1 ) . Those i n f a n t s exposed t o R beginning a t ( 30 wks X=25.0 wks g e s t a t i o n ) had a s i g n i f i c a n t l y g r e a t e r (pC.05) need f o r photoiherapy than did t h e i n f a n t s with exposure beginning a t >30 wks (X=32.8 wks g e s t a t i o n ) . Neither duration of exposure o r G A a t b i r t h were s i g n i f i c a n t f a c t o r s f o r hyperbilirubinemia. Early hypoglycemia was seen i n 111159 i n f a n t s (7%). 10111 of t h e s e i n f a n t s (91%) were exposed t o R u n t i l the day of delivery. This incidence d i f f e r e d s i g n i f i c a n t l y from t h a t among i n f a n t s whose exposure stopped a t l e a s t 1 week p r i o r t o delivery. Apgar scores, RDS,IUGR and m o r t a l i t y were n o t s i g n i f i c a n t l y d i f f e r e n t . I n conclusion, R therapy prolongs pregnancy and decreases premat u r i t y r a t e . Hyperbilirubinemia i s increased i n i n f a n t s exposed t o R e a r l i e r i n g e s t a t i o n r e g a r d l e s s of G A a t b i r t h . Hypoglycemia i s more frequent i n i n f a n t s exposed up until d e l i v q date.
The l a c e n t a i s n o t mere1 a p a s s i v e b a r r i e r t o drugs and for e i g n cgemicals but may p a r e i c i p a t e i n xenobiotic b i o t r a n s f o rmatlon a s well: I t i s n o t known whether chronic a
RESULTS: (17 Reductase a c t i v i t y (measured by neoprontosil r e d u c t i o n ) higher i n t h e s o l u b l e than microsomal f r a c t i o n s due mostly t o c a t a l y s i s b y NADPH No s i n i f i a n t d i f f e r e ce'was seen i n h e r e d u c t a s e act i v i t ; of 0 1 70.72 + 0.067 v+ a d g i c t j~. 7 t + 0 16) i n the supernate 2f Transfern e a c t i v l t y by b l i r u b f n conjugation) was minimal m both solubae and microsomal fractions. No s l g n if i c a n t d i f f e r e n c e was noted i n t h e microsomal t r a n s f e r a s e a c t iv i t y of c o n t r o l (0.11 + 0.06) v s a d d i c t (0.12 + 0.05) homogena t e s . (3) Mixed function oxidoreductase a c t i v i t y ( b a n i l i n e p-hydroxylation) a peared h i h e r i n t h e s o l u b l e ( 0 . 6 i + 0.24) than t h e microsoma! (0.21 + 8 . 1 4 ) f r a c t i o n s but due s o l a y t o hemoglobin i n t h e s o l u b l e f r a c t l o n whic nonenzymatically catal y s e s a n i l i n e hydroxylation (49.4 x 10-~umoleslmg Hgb). No enzymatic oxidoreductase a c t i v i t y was noted i n t h e c o n t r o l o r add i c t homogenates. CONCLUSION: L i t t l e t o no xenobiotic oxidoreductase and t r a n s f e r a s e a c t i v i t y was noted i n both c o n t r o l and a d d i c t p l a c e n t a l homogenates.
!
\?parent a c t i v i t y was p r i n c i p a l l y due t o nonenzymatic c a t a l y s i s of s u b s t r a t e s by NADPH o r H b Thus, d e s p i t e chronic exposure t o dru s t h e placenta of addicted mothers does n o t show any e n t a~c e d xenobiotic biotransformation a c t i v i t y and t h e r e f o r e o f f e r s no adaptive p r o t e c t i o n t o t h e f e t u s . ADVERSE EFFECTS OF MEPERIDINE (M), PROMETHAZINE (P)
401 AND CHLoRPRoMAzINE (c) COMBINATION FOR SEDATION/ ANESTHESIA I N PEDIATRIC PATIENTS. Milap C. Nahata, Michael A. Clotz and Elizabeth A. Krogg, Ohio S t a t e University Colleges of ?harmacy and Medicine, Children's Hospital Department of P e d i a t r i c s , Columbus, Ohio.
M (25 mglml), P (6.5 mglml) and C (6.5 mglml) combination i s widely used t o produce s e d a t i o n l a n e s t h e s i a i n p e d i a t r i c p a t i e n t s .
Although a dose of MPC, 0.1 mllkg, i s recommended f o r c a r d i a c c a t h e t e r i z a t i o n , no s p e c i f i c dosing g u i d e l i n e s and frequency of monitoring have been e s t a b l i s h e d f o r p a t i e n t s undergoing o t h e r procedures.
The adverse e f f e c t s of MPC were s t u d i e d prospect i v e l y i n 95 p a t i e n t s undergoing various procedures. MPC was given p a r e n t e r a l l y a t a dose df 0.02-0.20 ml/kg. V i t a l s i g n s , blood pressure, p u l s e r a t e and r e s p i r a t o r y r a t e were monitored during 8 h r a f t e r t h e dose. Four p a t i e n t s developed severe r e s p i r a t o r y depression.
I n t h e s e p a t i e n t s , t h e lowest r e s p i r at o r y r a t e ranged from 6 t o 18 per min a t 1 t o 3 h r . The lowest p u l s e r a t e ranged from 92 t o 102 per h r a t 1 t o 2 h r . One pat i e n t receiving MPC, 0.07 mllkg, developed r e s p i r a t o r y a r r e s t w i t h i n 30 min. One p a t i e n t required naloxone and a l l recovered w i t h i n 12 h r . About two-thirds of 95 p a t i e n t s were sedated f o r longer than 7 h r . These d a t a suggest t h e need f o r frequent monitoring and s p e c i f i c dosing g u i d e l i n e s f o r MPC u s e i n pediat r i c p a t i e n t s . Tobramycin i s commonly used i n newborn i n f a n t s but l i t t l e i s known about i t s ~h a r m a c o k i n e t i c s i n i d e n t i c a l twins. We s t u d i e d s i x i n f a n t s ( g e s t a t i o n a l age 29-31 weeks; p o s t n a t a l age 3-4 days; b i r t h weight 1.0-1.3 kg) receiving tobramycin 2.5 mglkg IV over 20 minutes every 12-18 hours. On t h i r d day of therapy, blood samples were c o l l e c t e d a t 0, 0.5, 1, 2, 4, 8 , 12 and 18 hours a f t e r s t a r t i n g t h e i n f u s i o n and analyzed by EMIT. Peak and trough serum concentrations of tobramycin ranged from 5.3-8.4 u g / d and 1.2-2.0 pglml, r e s p e c t i v e l y . T o t a l clearance ( c l~) ranged from 0.74-1.19 mllminlkg, d i s t r i b u t i o n volume (V) from 0.74-0.94 Llkg, and e l i m i n a t i o n h a l f -l i f e (t%) from 8.2-12.8 hours. Comparison of d a t a between i n f a n t s i n t h r e e i d e n t i c a l twin p a i r s showed t h a t d e s p i t e a s i m i l a r i n f u s i o n method:
(a) t h e time t o achieve peak serum concentration ranged from 0.5-2.0 hours; (b) t h e peak and trough concentrations v a r i e d from 0-50%; and (c) t h e c l~, V and tk v a r i e d from 3-20%. These d a t a indicate t h a t peak and trough serum concentrations may be more v a r i a b l e than t h e k i n e t i c parameters i n i d e n t i c a l twins. This information should be considered i n t h e r a p e u t i c drug monitoring of tobramycin i n i d e n t i c a l twins during t h e newborn period.
